IPA (ImmunoPrecise Antibodies) Change In Payables And Accrued Expense : $-0.38 Mil (TTM As of Jan. 2025)

View and export this data going back to 2010. Start your Free Trial

What is ImmunoPrecise Antibodies Change In Payables And Accrued Expense?

ImmunoPrecise Antibodies's Change In Payables And Accrued Expense for the quarter that ended in Jan. 2025 was $-0.77 Mil. It means ImmunoPrecise Antibodies's Accounts Payable & Accrued Expense declined by $0.77 Mil from Oct. 2024 to Jan. 2025 .

ImmunoPrecise Antibodies's Change In Payables And Accrued Expense for the fiscal year that ended in Apr. 2024 was $0.72 Mil. It means ImmunoPrecise Antibodies's Accounts Payable & Accrued Expense increased by $0.72 Mil from Apr. 2023 to Apr. 2024 .

ImmunoPrecise Antibodies Change In Payables And Accrued Expense Historical Data

The historical data trend for ImmunoPrecise Antibodies's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmunoPrecise Antibodies Change In Payables And Accrued Expense Chart

ImmunoPrecise Antibodies Annual Data

Trend

Dec14

Dec15

Apr17

Apr18

Apr19

Apr20

Apr21

Apr22

Apr23

Apr24

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

0.12

0.70

1.16

-1.24

0.72

ImmunoPrecise Antibodies Quarterly Data
	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24	Jan25
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															0.58	-0.35	0.39	0.36	-0.77

ImmunoPrecise Antibodies Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Jan. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.38 Mil.

ImmunoPrecise Antibodies Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of ImmunoPrecise Antibodies's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

ImmunoPrecise Antibodies Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmunoPrecise Antibodies Ltd (NAS:IPA) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

TQB:Germany

Address

Industrious 823 Congress Avenue, Suite 300, Austin, TX, USA, 78701

Website

https://www.ipatherapeutics.com

ImmunoPrecise Antibodies Ltd is a techbio company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges. IPA has several subsidiaries in North America and Europe.